On September 2, 2021, 10 thousand doses of Casirivimab/Imdevimab for the treatment of coronavirus were delivered from Berlin to Tashkent. The cost of the cargo is 20.6 million euros.

At the initiative of OPASCA GmbH, together with the Ministry of Health of the Republic of Uzbekistan, an online meeting was held on September 8 on the use of the latest highly effective drug Casirivimab/Imdevimab against coronavirus in medical institutions.

The event was attended by Deputy Minister of Health Ulugbek Sabirov, Dr. Alexey Sverdlov, CEO of OPASCA GmbH, Dr. Andreas Jansen, Deputy Head of the Center for International Health Protection of the Robert Koch Institute (RKI, Germany), Dr. Karin Steinke, Senior Doctor of the Charite University Hospital (Berlin).

A general description of Casirivimab/Imdevimab was given, the method of application and possible side effects were discussed at the meeting. Casirivimab/Imdevimab is a so-called artificial “cocktail of antibodies” created to protect against COVID-19. The combination of several antibodies prevents the development of COVID-19 in patients and increases the body's resistance to various mutations of the virus.

As it was noted at the meeting, German specialists’ researches showed that the drug reduced hospitalization and mortality from coronavirus by 70 percent, and also reduced the duration of symptoms from 14 to 10 days. It can be used in the treatment of COVID-19 to prevent the progression of the disease to a severe form in patients at risk, the development of serious complications with subsequent hospitalization.

It was also emphasized that the relations provide an opportunity to work together, support and study the German experience in the fight against COVID-19 during the pandemic.

 Nasiba Ziyodullayeva, UzA